The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
Study Rationale: The protein alpha-synuclein forms abnormal aggregates in the brains of people with Parkinson's disease (PD). Although the mechanism by which this aggregation leads to the pathological...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Testing the Neuroprotective Effects of Modulating Atp6v0a1
Study Rationale: Parkinson’s disease (PD) is associated with the death of dopamine-producing neurons. Neuroprotective strategies that could maintain these critical cells would provide a much-needed...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Development of Immune-based Biomarkers for Parkinson’s Disease
Study Rationale: Preclinical and human studies have demonstrated the potential of using granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of Parkinson’s disease (PD). GM-CSF...
-
Fall 2021 RFP: Outcome Measures, 2021Development and Validation of a Sensitive Method for Measuring PINK
Study Rationale: Mutations in PINK1 are linked to familial Parkinson’s disease (PD), but their role in sporadic forms of the disorder are not clear. The PINK1 protein works with PRKN to dispose of...
-
Research Grant, 2021Exploring the Protective Effect of Modulating Brain Cells’ Electrical Activity in Parkinson’s Disease
Study Rationale: The symptoms of Parkinson’s disease (PD) arise when more than 70% of the dopamine-producing neurons in the brain region regulating movement are lost. This disruption increases the...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2021Studying How Defects in Autophagy Contribute to the Aggregation of Alpha-synuclein in Neurons with LRRK2 Mutations
Study Rationale: Mutations in the LRRK2 gene are the most frequent cause of inherited forms of Parkinson’s disease (PD). We have found that these mutations disrupt autophagy—a process that cells...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.